Clinical and Laboratory Transition Between GPA and EGPA Authors: Sergey V. Fedosenko, Mats Junek, Carmen Venegas Garrido, Sarita Thawanaphong, Nadia Suray Tan, Sarah Svenningsen, Manali Mukherjee, Nader Khalidi, Parameswaran Nair Published: 2026 ABSTRACT Granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) are recognized subtypes of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Their clinical boundaries, however, may be more dynamic than assumed. We describe 2 patients illustrating sequential phenotype transitions with prominent respiratory involvement. The first patient was initially diagnosed with GPA, presenting with neuropathy, purpura, epistaxis, renal disease, and myeloperoxidase (MPO)-ANCA positivity. Six years later, she developed asthma, marked eosinophilia, and eosinophilic myocarditis, consistent with evolution toward EGPA despite stable ANCA serology. The second patient was first classified as EGPA based on eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and MPO-ANCA with borderline proteinase 3 (PR3)-ANCA. After SARS-CoV-2 infection, he developed GPA-like disease with strongly positive PR3-ANCA and destructive airway involvement, including tracheobronchomalacia requiring tracheostomy and stenting. These cases highlight that recognizing this dynamic nature is essential for the timely reassessment of disease classification, prognosis, and therapeutic approach in AAV. Granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) are subtypes of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).1 Classification usually relies on clinical, laboratory, radiologic, and histopathologic findings. However, features and serology may evolve over time, potentially altering diagnosis, prognosis, and treatment. We present 2 patients initially meeting criteria for 1 AAV phenotype who later developed features of another, both with prominent respiratory involvement (details are shown in Figure 1 and Table 1).Figure 1Evolution of disease phenotype and ANCA profile in 2 patients with ANCA-associated vasculitis (AAV). Clinical trajectories of 2 patients demonstrating a shift in disease phenotype between GPA and EGPA over time. Patient 1 (female, 49 years old) was initially diagnosed with GPA, later fulfilling criteria for EGPA. Patient 2 (male, 54 years old) was initially diagnosed with EGPA and subsequently evolved toward a GPA-like phenotype. Both patients met multiple 2022 ACR/EULAR classification criteria at different time points. Biomarker dynamics (MPO-ANCA/PR3-ANCA), eosinophil counts, respiratory symptoms, imaging changes, and treatment responses are depicted. ACR/EULAR = American College of Rheumatology/European Alliance of Associations for Rheumatology; AI = antibody index (assessed by Bioplex microarray enzyme-linked immunosorbent assay); ANCA = anti-neutrophil cytoplasmic antibodies; BAFF = B-cell activating factor; BENRA = benralizumab (30 mg 3 doses every 4 weeks, then every 8 weeks); CNS = central nervous system; CPAP = continuous positive airway pressure; CRwNP = chronic rhinosinusitis with nasal polyps; DUPI = dupilumab; EGPA = eosinophilic granulomatosis with polyangiitis; EMG = electromyography; Feno = fractional exhaled nitric oxide; GPA = granulomatosis with polyangiitis; HRCT = high-resolution computed tomography; MEPO = mepolizumab (100 mg every 4 weeks); MMF = mycophenolate mofetil; MPA = microscopic polyangiitis; MPO-ANCA = myeloperoxidase-antineutrophil cytoplasmic antibody; OMA = omalizumab (300 mg every 4 weeks); PR3-ANCA = proteinase 3-antineutrophil cytoplasmic antibody; TNFα = tumor necrosis factor alpha. ∗Sputum cytokine assay (Ella, ProteinSimple, a Bio-Techne brand, USA; 1:2 dilution) revealed elevated levels of IL-4 (3.69 pg/mL; ref. ≤ 0.5342 pg/mL), IL-13 (8.06 pg/mL; ref. ≤ 3.596 pg/mL), and IL-5 (3.38 pg/mL; ref. ≤ 0.4936 pg/mL). ∗∗Sputum cytokine assay (Ella, ProteinSimple, a Bio-Techne brand, USA; 1:2 dilution) revealed elevated levels of non-Th2 cytokines, including IL-1β (2,156 pg/mL; ref. ≤ 107.54 pg/mL), IL-18 (83.8 pg/mL; ref. ≤ 54.1 pg/mL), TNF-α (8 pg/mL; ref. ≤ 2.488 pg/mL), and BAFF (143 pg/mL; ref. ≤ 25.88 pg/mL).Table 1Laboratory Findings at Baseline (T0) and at Vasculitic Phenotype Transition (T1)Laboratory Parameters, Reference RangesPatient 1Patient 2T0 (GPA)T1 (EGPA)T0 (EGPA)T1 (GPA)Blood cells Leukocytes, 4.0-11.0 × 109/L5.9-12.54.7-10.74.5-16.76.7-13.8 Neutrophils, 2.0-7.5 × 109/L4.3-11.43.2-10.24.06-10.95.6-10.0 Eosinophils, < 0.4 × 109/L0-0.20.6-8.21.0-9.10.0 Lymphocytes, 1.0-3.5 × 109/L0.8-1.20.7-1.70.5-1.820.5-1.64 Erythrocytes, 4.0-5.9 ×1012/L (sex-dependent)4.24-4.724.28-4.794.85-5.024.02-5.19 Hemoglobin, 120-160 g/L (sex-dependent)116-128126-147152-156129-156 Platelets, 150-400 × 109/L174-329234-333163-317165-295Serum biomarkers PR3-ANCA, < 0.2 AI (assay-dependent)< 0.2< 0.2< 0.2-0.51.1- > 8.0 MPO-ANCA, < 0.2 AI (assay-dependent)> 8.03.1-7.95.8< 0.2 ANA/ENA, negative (qualitative ± titer)Positive, 1:320NegativeNegativeNegative Rheumatoid factor, < 20 IU/mL< 20< 20< 20< 20 CRP, < 5.0 mg/L34.8-103.929.1-147< 5.0-101< 5.0-137 ESR, 0-20 mm/h (age- and sex-dependent)19-506-24N/A3-50 Creatinine, 67-117 μmol/L (sex-dependent)76-9668-9376-8466-87 Tryptase, 3.8-11.4 μg/L4.85.0N/AN/A IgA, 0.7-3.52 g/L1.37-1.831.4-1.641.78-2.10.98-1.18 IgM, 0.41-2.07 g/L0.42-1.090.61-0.860.38-0.740.57-0.62 IgG, 6.35-14.65 g/L8.69-9.98.63-9.375.7-9.746.8-7.44 IgG4, 39-864 mg/LN/AN/A814499 IgE, <87 kIU/L1012647-50N/A C3 complement, 0.8-1.7 g/L1.63N/AN/A1.88 C4 complement, 0.16-0.52 g/L0.26N/AN/A0.29 Troponin I (high sensitivity), < 17 ng/L (< 99th percentile; assay- and sex-dependent)2.09,441< 2.0< 2.0 NT-proBNP, ≤125 ng/L (age-dependent)N/A10,157N/A65-160Urinalysis Blood/erythrocytes (qualitative), negative+++++NegativeNegative - trace Protein, negative/0 g/L0.29-1.0++Negative0.3T0 denotes baseline laboratory assessment, and T1 denotes laboratory assessment at the time of vasculitic phenotype transition. Ranges represent observed values during the corresponding period. “N/A” indicates that the parameter was not assessed. AI = antibody index; ANA = antinuclear antibodies; ANCA = antineutrophil cytoplasmic antibodies; CRP = C-reactive protein; EGPA = eosinophilic granulomatosis with polyangiitis; ENA = extractable nuclear antigens; ESR = erythrocyte sedimentation rate; GPA = granulomatosis with polyangiitis; MPO = myeloperoxidase; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PR3 = proteinase 3. Evolution of disease phenotype and ANCA profile in 2 patients with ANCA-associated vasculitis (AAV). Clinical trajectories of 2 patients demonstrating a shift in disease phenotype between GPA and EGPA over time. Patient 1 (female, 49 years old) was initially diagnosed with GPA, later fulfilling criteria for EGPA. Patient 2 (male, 54 years old) was initially diagnosed with EGPA and subsequently evolved toward a GPA-like phenotype. Both patients met multiple 2022 ACR/EULAR classification criteria at different time points. Biomarker dynamics (MPO-ANCA/PR3-ANCA), eosinophil counts, respiratory symptoms, imaging changes, and treatment responses are depicted. ACR/EULAR = American College of Rheumatology/European Alliance of Associations for Rheumatology; AI = antibody index (assessed by Bioplex microarray enzyme-linked immunosorbent assay); ANCA = anti-neutrophil cytoplasmic antibodies; BAFF = B-cell activating factor; BENRA = benralizumab (30 mg 3 doses every 4 weeks, then every 8 weeks); CNS = central nervous system; CPAP = continuous positive airway pressure; CRwNP = chronic rhinosinusitis with nasal polyps; DUPI = dupilumab; EGPA = eosinophilic granulomatosis with polyangiitis; EMG = electromyography; Feno = fractional exhaled nitric oxide; GPA = granulomatosis with polyangiitis; HRCT = high-resolution computed tomography; MEPO = mepolizumab (100 mg every 4 weeks); MMF = mycophenolate mofetil; MPA = microscopic polyangiitis; MPO-ANCA = myeloperoxidase-antineutrophil cytoplasmic antibody; OMA = omalizumab (300 mg every 4 weeks); PR3-ANCA = proteinase 3-antineutrophil cytoplasmic antibody; TNFα = tumor necrosis factor alpha. ∗Sputum cytokine assay (Ella, ProteinSimple, a Bio-Techne brand, USA; 1:2 dilution) revealed elevated levels of IL-4 (3.69 pg/mL; ref. ≤ 0.5342 pg/mL), IL-13 (8.06 pg/mL; ref. ≤ 3.596 pg/mL), and IL-5 (3.38 pg/mL; ref. ≤ 0.4936 pg/mL). ∗∗Sputum cytokine assay (Ella, ProteinSimple, a Bio-Techne brand, USA; 1:2 dilution) revealed elevated levels of non-Th2 cytokines, including IL-1β (2,156 pg/mL; ref. ≤ 107.54 pg/mL), IL-18 (83.8 pg/mL; ref. ≤ 54.1 pg/mL), TNF-α (8 pg/mL; ref. ≤ 2.488 pg/mL), and BAFF (143 pg/mL; ref. ≤ 25.88 pg/mL). Table 1Laboratory Findings at Baseline (T0) and at Vasculitic Phenotype Transition (T1)Laboratory Parameters, Reference RangesPatient 1Patient 2T0 (GPA)T1 (EGPA)T0 (EGPA)T1 (GPA)Blood cells Leukocytes, 4.0-11.0 × 109/L5.9-12.54.7-10.74.5-16.76.7-13.8 Neutrophils, 2.0-7.5 × 109/L4.3-11.43.2-10.24.06-10.95.6-10.0 Eosinophils, < 0.4 × 109/L0-0.20.6-8.21.0-9.10.0 Lymphocytes, 1.0-3.5 × 109/L0.8-1.20.7-1.70.5-1.820.5-1.64 Erythrocytes, 4.0-5.9 ×1012/L (sex-dependent)4.24-4.724.28-4.794.85-5.024.02-5.19 Hemoglobin, 120-160 g/L (sex-dependent)116-128126-147152-156129-156 Platelets, 150-400 × 109/L174-329234-333163-317165-295Serum biomarkers PR3-ANCA, < 0.2 AI (assay-dependent)< 0.2< 0.2< 0.2-0.51.1- > 8.0 MPO-ANCA, < 0.2 AI (assay-dependent)> 8.03.1-7.95.8< 0.2 ANA/ENA, negative (qualitative ± titer)Positive, 1:320NegativeNegativeNegative Rheumatoid factor, < 20 IU/mL< 20< 20< 20< 20 CRP, < 5.0 mg/L34.8-103.929.1-147< 5.0-101< 5.0-137 ESR, 0-20 mm/h (age- and sex-dependent)19-506-24N/A3-50 Creatinine, 67-117 μmol/L (sex-dependent)76-9668-9376-8466-87 Tryptase, 3.8-11.4 μg/L4.85.0N/AN/A IgA, 0.7-3.52 g/L1.37-1.831.4-1.641.78-2.10.98-1.18 IgM, 0.41-2.07 g/L0.42-1.090.61-0.860.38-0.740.57-0.62 IgG, 6.35-14.65 g/L8.69-9.98.63-9.375.7-9.746.8-7.44 IgG4, 39-864 mg/LN/AN/A814499 IgE, <87 kIU/L1012647-50N/A C3 complement, 0.8-1.7 g/L1.63N/AN/A1.88 C4 complement, 0.16-0.52 g/L0.26N/AN/A0.29 Troponin I (high sensitivity), < 17 ng/L (< 99th percentile; assay- and sex-dependent)2.09,441< 2.0< 2.0 NT-proBNP, ≤125 ng/L (age-dependent)N/A10,157N/A65-160Urinalysis Blood/erythrocytes (qualitative), negative+++++NegativeNegative - trace Protein, negative/0 g/L0.29-1.0++Negative0.3T0 denotes baseline laboratory assessment, and T1 denotes laboratory assessment at the time of vasculitic phenotype transition. Ranges represent observed values during the corresponding period. “N/A” indicates that the parameter was not assessed. AI = antibody index; ANA = antinuclear antibodies; ANCA = antineutrophil cytoplasmic antibodies; CRP = C-reactive protein; EGPA = eosinophilic granulomatosis with polyangiitis; ENA = extractable nuclear antigens; ESR = erythrocyte sedimentation rate; GPA = granulomatosis with polyangiitis; MPO = myeloperoxidase; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PR3 = proteinase 3. Laboratory Findings at Baseline (T0) and at Vasculitic Phenotype Transition (T1) T0 denotes baseline laboratory assessment, and T1 denotes laboratory assessment at the time of vasculitic phenotype transition. Ranges represent observed values during the corresponding period. “N/A” indicates that the parameter was not assessed. AI = antibody index; ANA = antinuclear antibodies; ANCA = antineutrophil cytoplasmic antibodies; CRP = C-reactive protein; EGPA = eosinophilic granulomatosis with polyangiitis; ENA = extractable nuclear antigens; ESR = erythrocyte sedimentation rate; GPA = granulomatosis with polyangiitis; MPO = myeloperoxidase; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PR3 = proteinase 3. Case Report 1: Evolution of GPA Into EGPA In 2015, a 49-year-old White woman of Mediterranean origin presented with fever, malaise, peripheral neuropathy, recurrent epistaxis, microhematuria, palpable purpura on her lower extremities, and strongly positive serum myeloperoxidase (MPO)-ANCA (> 8.0 AI; Bioplex microarray enzyme-linked immunosorbent assay) in the absence of blood eosinophilia (peak of 0.2 × 109/L on several measurements, without glucocorticosteroid therapy). At the time of GPA diagnosis, asthma was not supported by clinical history, symptoms, or spirometric evidence of variable airflow obstruction; bronchial provocation testing was not performed because of lack of indication. Endoscopic examination and CT imaging of the nasal cavity and paranasal sinuses showed no evidence of nasal polyposis. Electromyography and sural nerve biopsy confirmed mononeuritis multiplex. She was diagnosed with GPA and treated with cyclophosphamide induction (15 mg/kg, 10 infusions), then azathioprine (2 mg/kg/day) alongside prednisone for maintenance. Two years later, while on azathioprine, she developed asthma, confirmed by methacholine challenge, and was prescribed inhaled therapy. Four years later, she experienced worsening dyspnea, cough, and fatigue with marked eosinophilia (8.2 × 109/L) and eosinophilic myocarditis (troponins 9,681 ng/L; myocardial edema and subepicardial late gadolinium enhancement on MRI). Extensive workup excluded hematologic, genetic, and infectious causes of eosinophilia. Serum MPO-ANCA levels were persistently elevated (3.1-7.9 AI); proteinase 3 (PR3)-ANCA remained negative. AAV was reclassified as EGPA and treated with IV methylprednisolone (1,000 mg daily for 3 days), followed by oral prednisone and IV rituximab (500 mg every 6 months), leading to resolution of eosinophilia and normalization of cardiac MRI and enzymes. On subsequent follow-up, she reported occasional epistaxis and neuropathic pain, while asthma remained controlled with normalized lung function. Blood tests revealed undetectable eosinophils and CD19 cells and mildly decreased IgG levels, and MPO-ANCA declined. Treatment with rituximab and low-dose prednisone (5 mg/day) has been continued. Case Report 2: Clinical and Laboratory Shift From EGPA to GPA A 54-year-old White man presented with recurrent nasal polyposis and poorly controlled asthma despite step 5 Global Initiative for Asthma therapy, including prednisone (5-10 mg/day), omalizumab, and, later, mepolizumab (100 mg every 4 weeks). Given persistent blood eosinophilia (1.0 × 109/L), he was transitioned to benralizumab (30 mg every 8 weeks). After 4 injections, blood and sputum eosinophils were depleted. However, the patient demonstrated recurrent chest infections requiring antibiotics, progressive lung function decline, persistent nasal congestion with anosmia, and chronic right-sided otitis media with mixed hearing loss. Both serum (MPO-ANCA, 5.8 AI) and sputum (indirect immunofluorescence) were p-ANCA-positive. Chest high-resolution CT scan showed mild cylindrical bronchiectasis and a small left upper-lobe ground-glass opacity. Sinus imaging indicated diffuse polypoid pansinusitis. Benralizumab was discontinued, and 6 months later, peripheral eosinophils (0.4 × 109/L), sputum eosinophils (75%), and fractional exhaled nitric oxide (Feno, 227 ppb) rose, with worsening asthma control. Concurrently, serum PR3-ANCA became borderline detectable (0.5 AI), and sputum T2-cytokines (IL-4, IL-13, IL-5) were elevated.2 Given predominant rhinosinusitis, dupilumab was initiated along with prednisone, leading to improvement in sinonasal symptoms, asthma control, lung function, and normalization of eosinophil counts (< 0.4 × 109/L) and Feno (16 ppb), allowing prednisone tapering from 10 to 5 mg/day. After a negative serum c-/p-ANCA result by enzyme-linked immunosorbent assay, both serum and sputum tested negative by indirect immunofluorescence.3 A year later, while maintained on dupilumab, the patient contracted COVID-19 and developed marked hypereosinophilia (9.1 × 109/L), bilateral pulmonary infiltrates, and a thick-walled right lower lobe cavity. Prednisone (50 mg/day) led to radiologic and clinical improvement. Nevertheless, recurrent right eosinophilic otitis media and mastoiditis (biopsy-confirmed), blood eosinophilia (1.7 × 109/L), and severe dry cough prompted re-initiation of mepolizumab (100 mg subcutaneously every 4 weeks) along with dupilumab. Despite eosinophil suppression and normalization of Feno, symptoms progressed, accompanied by elevated C-reactive protein (49.3 mg/L) and PR3-ANCA (> 8.0 AI), whereas MPO-ANCA remained undetectable. Cardiac MRI demonstrated subtle subepicardial enhancement. Over the following year, sinonasal symptoms worsened, and pulmonary function declined, with exertional dyspnea, wheezing/stridor, and persistent dry cough with hoarseness. Prednisone (40 mg/day) plus mycophenolate mofetil proved ineffective. Oscillometry confirmed large airway involvement, and flow-volume loops showed increased collapsibility. Imaging demonstrated new concentric tracheobronchial wall thickening and expiratory collapse (Fig 2). Bronchoscopy showed superficial tracheal inflammation with ulcers and severe tracheobronchomalacia with complete posterior wall collapse, although biopsies were nondiagnostic. CPAP yielded minimal benefit and only slight improvement in exercise tolerance.Figure 2Axial high-resolution CT scan images of the chest obtained during the inspiratory (1—left column) and expiratory (2—right column) phases at multiple levels of the central airways, from the upper trachea to the lower trachea and mainstem bronchi (A-F). Dynamic expiratory airway collapse (marked with arrows) is evident, with significant narrowing of the tracheal lumen and anterior bowing of the posterior membranous wall, consistent with tracheomalacia. Axial high-resolution CT scan images of the chest obtained during the inspiratory (1—left column) and expiratory (2—right column) phases at multiple levels of the central airways, from the upper trachea to the lower trachea and mainstem bronchi (A-F). Dynamic expiratory airway collapse (marked with arrows) is evident, with significant narrowing of the tracheal lumen and anterior bowing of the posterior membranous wall, consistent with tracheomalacia. Worsening ventilation required straight tracheal stent placement, which proved ineffective. Given active tracheal inflammation, tracheoplasty was considered too risky. The shift in AAV phenotype (from eosinophil-predominant to erosive disease) along with treatment refractoriness and serologic evolution (MPO- to PR3-ANCA) established a GPA diagnosis. Sputum Th2 cytokine levels (IL-4, IL-5, and IL-13), typically elevated in EGPA, were within normal limits, and non-Th2 cytokines (IL-1β, IL-18, tumor necrosis factor-alpha [TNF-α], B-cell activating factor [BAFF]) linked to inflammasome and B-cell activity were markedly increased.2 He was treated with cyclophosphamide (15 mg/kg, 10 doses) and prednisone (60 mg/day with slow tapering). Additional maintenance immunosuppression was deferred out of concern for infectious complications. Mepolizumab was discontinued, and tracheostomy with replacement of the straight stent by a Y-shaped stent yielded transient improvement in dyspnea, cough, and spirometry. Shortly after, the patient developed a presumed viral illness followed by severe cough and copious frothy sputum. Gastroesophageal reflux was presumed to contribute to airway secretions and confirmed by elevated sputum pepsin (26.85 ng/mL after 1:10 dilution; nearly 7-fold above the assay limit of 4.00 ng/mL). Sputum became purulent and grew multidrug-resistant Pseudomonas aeruginosa, which persisted despite eradication attempts with nebulized tobramycin and IV piperacillin–tazobactam, suggesting airway colonization. Although immunosuppression may have contributed to this, extended testing (383 genes, Blueprint Genetics) for primary immunodeficiencies and ciliary dyskinesia revealed a heterozygous intronic cystic fibrosis transmembrane conductance regulator variant (c.1210-33_1210-6GT[12]T[4]), considered nonpathogenic but potentially a modifier. Treatment with nebulized tobramycin and 7% saline, dupilumab, prednisone (5 mg/day), inhaled corticosteroid/long-acting β2-agonist/long-acting muscarinic antagonist, esomeprazole, frequent tracheal suctioning, and nocturnal СPAP has partially stabilized his condition, reduced sputum volume, and improved FEV1 from 0.85 L to 1.35 L (39.5% predicted). Discussion Initially classified as GPA, the first case was notable for persistent MPO-ANCA positivity throughout the clinical history. Early phenotyping was challenging because the clinical and laboratory features preceding late-onset asthma, eosinophilia, and cardiomyopathy were nonspecific and overlapped across AAV subtypes.4 Recurrent epistaxis supported a diagnosis of GPA vs microscopic polyangiitis. The subsequent emergence of asthma with blood hypereosinophilia (EGPA hallmarks) suggests a phenotypic transformation of unclear origin. Initially presenting as MPO-ANCA-positive EGPA, the second patient developed PR3-ANCA elevation and severe tracheobronchomalacia after SARS-CoV-2 infection. Acquired tracheomalacia is rarely described outside of ventilated patients with COVID-19 or those with vasculitis unless tracheal chondritis is present, although it may occur in obstructive airway diseases and be predisposed by prolonged glucocorticosteroid use5 and gastroesophageal reflux disease,6 both present here. Ulcerative tracheal damage with marked PR3-ANCA elevation aligned more with GPA, suggesting transition in disease pattern.7 The cystic fibrosis transmembrane conductance regulator 5T variant (despite uncertain pathogenicity), combined with immunosuppression, tracheobronchomalacia, and excessive airway secretions, likely promoted infection and persistent neutrophilic, possibly inflammasome-driven inflammation with B-cell activation. Such activation may impair immune tolerance and foster ANCA autoimmunity. Although rare, ANCA serotype changes can occur in EGPA. Jinno et al8 reported a patient with EGPA who switched from PR3- to MPO-ANCA and later became dual-positive, with no clear cause.8 COVID-19 might contribute by inducing de novo autoantibodies and new-onset autoimmunity.9 In other AAV forms, treatment may influence ANCA specificity, although this is poorly understood in EGPA.10 We hypothesize that shifts between AAV subtypes reflect dysregulated immune tolerance and altered antigen presentation, potentially enabling epitope spreading or clonal B-cell expansion with new autoreactivities. The use of dupilumab in EGPA remains controversial. In a European retrospective study, approximately one-third of patients experienced EGPA relapse during dupilumab therapy, often associated with peripheral blood eosinophilia.11 In case 2, dupilumab was initiated for refractory rhinosinusitis in the setting of stable prednisone dosing and suppressed blood eosinophils, guided by airway biomarker findings (including sputum ANCA and elevated IL-13), suggestive of IL-13-dominant inflammation associated with localized airway immune dysregulation.3,12 This was associated with sustained improvement in airway symptoms and lung function, normal Feno and eosinophil levels, successful glucocorticoid tapering, and 1 year of clinical stability. Although it remains uncertain whether the subsequent relapse with recurrent hypereosinophilia was directly related to dupilumab, this observation highlights the need for particular caution when considering its use in EGPA until more robust safety data are available. Other smaller case series have also reported improvement in sinonasal symptoms with dupilumab in patients with EGPA.13 However, we do not recommend dupilumab monotherapy (without adequate concomitant prednisone) for patients with raised blood (> 1.5 × 109 cells/L) or sputum (> 15%-20%) eosinophils. Notably, both patients were MPO-ANCA-positive at disease onset. Clinical and genetic cohort data indicate that MPO- and PR3-AAVs represent biologically and clinically distinct subgroups with different patterns of organ involvement and disease expression, supporting the concept that classification by ANCA serotype may provide clinically meaningful insights beyond traditional phenotype-based categorization.14 Finally, differentiating AAVs remains challenging, even for experienced clinicians, and ANCA serology does not always simplify this distinction. For example, PR3-ANCA-positive disease, although classically associated with GPA, may exhibit substantial clinical and histopathologic heterogeneity, with phenotypes that evolve over time.15 This highlights the dynamic nature of vasculitis and the need for ongoing reassessment and timely management. Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: S. F. reports honoraria from AstraZeneca. C. V. G. reports fees from AstraZeneca and GlaxoSmithKline. S. S. reports grants from Cyclomedica Australia Pty Ltd, Genentech Inc., and Trudell Medical, and fees from Polarean Imaging plc, GSK, and Cyclomedica. M. M. is supported by the AstraZeneca Chair in Respiratory Diseases and has received grants from Methapharm, Sanofi, Mirimus, JN Nova, the Canadian Asthma Allergy and Immunology Foundation, and the Canadian Institutes of Health Research, as well as honoraria from AstraZeneca, GSK, Sanofi, Respiplus, and EAACI. N. K. reports institutional payments from Roche, AbbVie, Otsuka, GSK, and Mallinckrodt; fees from AstraZeneca; and trial payments from BMS, AbbVie, Sanofi, and NS Pharma. P. N. reports grants from AstraZeneca, Teva, Roche, Novartis, Sanofi, Cyclomedica, and Foresee, and fees from AstraZeneca, Teva, Roche, GSK, Arrowhead, and Methapharm. All outside the submitted work. None declared (M. J., S. T., N. S. T.)